Clinical trials: Rivaroxaban
Sickle Cell Disease, Central Venous Catheter Thrombosis
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)
Research Question: In adult SCD patients with CVC, is it feasible and safe to conduct an adequately powered RCT to evaluate the use of rivaroxaban as thromboprophylaxis in this population? Study Design: The study is a vanguard…
- Conditions
- Sickle Cell Disease, Central Venous Catheter Thrombosis, Venous Thromboembolism
- Trial name
- THIS (NCT05033314)
- Testing
- Rivaroxaban 10 MG
- Where
- 3 sites in Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Peripheral Arterial Disease, Venous Thormboembolism
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures.
- Conditions
- Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases, Vascular Surgery Patient with PAD / Carotid Stenosis
- Trial name
- RESOLUTION (NCT06873321)
- Testing
- rivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- Science Valley Research Institute
Postpartum, VTE Prophylaxis
Excretion of Rivaroxaban in Human Breast Milk
The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.
- Conditions
- Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism), Rivaroxaban
- Trial name
- LACT (NCT06831474)
- Testing
- Rivaroxaban 10 MG Oral Tablet, Rivaroxaban 20 MG Oral Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Healthy Volunteers
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments").
- Trial name
- NCT06444178
- Testing
- Aspirin, REGN9933, REGN7508
- Where
- United Kingdom
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atrial Fibrillation, Recurrent Venous Thromboembolism
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
- Trial name
- MACACOD (NCT04042155)
- Testing
- dabigatran, rivaroxaban, apixaban or edoxaban
- Where
- Spain
- Volunteers
- 1,600 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Deep Vein Thrombosis, Postthrombotic Syndrome
Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
The randomized clinical study aimed to assess the efficacy and safety of standard anticoagulation with rivaroxaban in combination with diosmin compared to the isolated use of standard rivaroxaban for prolonged therapy of acute…
- Trial name
- RIDILOTT-DVT (NCT03413618)
- Testing
- Rivaroxaban, Diosmin, compression stockings
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Pirogov Russian National Research Medical University
Behcet Syndrome
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.
- Trial name
- ACTOR (NCT06780462)
- Testing
- Corticosteroids + Rivaroxaban, Corticosteroids alone
- Where
- 17 sites in France
- Volunteers
- 134 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2).
- Trial name
- XARENO (NCT02663076)
- Where
- 121 sites in Austria, Belgium and 3 more
- Volunteers
- 1,700 people
- Sponsor
- GWT-TUD GmbH
Acute Coronary Syndrome
Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS
A prospective, randomised, open label study of 3 clinically licensed treatments for ACS to assess the effects of these treatments on blood tests of endogenous fibrinolysis.
- Trial name
- VaLiDate-R (NCT03775746)
- Testing
- Clopidogrel 75Mg Tablet, Rivaroxaban 2.5Mg Tablet, Ticagrelor 90Mg Tablet
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- East and North Hertfordshire NHS Trust
Acute Pulmonary Embolism
Mechanical Thrombectomy for Acute Pulmonary Embolism
Research Objective: To prospectively compare the efficacy and safety of a pre-collaboratively developed ultra-thin PTFE minimally invasive thrombectomy system versus standard pharmacological therapy in patients with acute…
- Trial name
- NCT07032025
- Testing
- Innovative Device Group, Standard Pharmacological Therapy Group
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Patients Receiving Rivaroxaban Treatment
Validation of Rivaroxaban Assay for US Registration
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma…
- Trial name
- NCT02333929
- Testing
- STA- Rivaroxaban Calibrator&Control
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Diagnostica Stago
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Thromboembolism, Prevention
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Patients undergoing surgery, especially hip and knee surgery, are at high risk for VTE (up to 60 % without prophylaxis). The administration of drugs for thromboprophylaxis, such as heparins, significantly lowers that risk, but…
- Trial name
- ODiXaHip (NCT00839826)
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Austria, Belgium and 9 more
- Volunteers
- 641 people
- Sponsor
- Bayer